- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CDK4/6 inhibition in luminal breast cancer ; day:20 ; month:6 ; year:2016 ; pages:1-6
Magazine of European Medical Oncology ; (20.6.2016), 1-6
- Urheber
-
Gampenrieder, Simon Peter
- Beteiligte Personen und Organisationen
-
Rinnerthaler, Gabriel
Greil, Richard
SpringerLink (Online service)
- DOI
-
10.1007/s12254-016-0268-2
- URN
-
urn:nbn:de:1111-201606223086
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gampenrieder, Simon Peter
- Rinnerthaler, Gabriel
- Greil, Richard
- SpringerLink (Online service)
Ähnliche Objekte (12)
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
Position paper on CDK4/6 inhibitors in early breast cancer
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
GRHL2-controlled gene expression networks in luminal breast cancer
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
Position paper on CDK4/6 inhibitors in early breast cancer
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
GRHL2-controlled gene expression networks in luminal breast cancer
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination
Position paper on CDK4/6 inhibitors in early breast cancer
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
GRHL2-controlled gene expression networks in luminal breast cancer
Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors